Aligos Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $3.6M | $6.2M | $0 | $0 | $0 | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $69.5M | $70.3M | $73.0M | $85.1M | $104.2M | $79.9M | $44.0M |
| SG&A Expense | $20.7M | $22.8M | $30.6M | $26.4M | $28.5M | $17.9M | $10.0M |
| Operating Income | $-88.0M | $-89.2M | $-88.1M | $-97.6M | $-128.3M | $-97.8M | $-54.0M |
| Operating Margin | -4,024.9% | -2,469.0% | -1,423.5% | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | $-23.9M | $-130.9M | $-86.9M | $-95.9M | $-128.2M | $-108.4M | $-52.2M |
| Income Tax Expense | $314.0K | $331.0K | $795.0K | $106.0K | $143.0K | $161.0K | $85.0K |
| Net Income | $-24.2M | $-131.2M | $-87.7M | $-96.0M | $-128.3M | $-108.5M | $-52.3M |
| Net Margin | -1,106.7% | -3,633.6% | -1,416.2% | — | — | — | — |
| EPS (Basic) | $-2.45 | $-20.94 | $-17.10 | $-1.13 | $-1.61 | $-5.44 | $-13.02 |
| EPS (Diluted) | $-2.45 | $-20.94 | $-17.10 | $-1.13 | $-1.61 | $-5.44 | $-13.02 |
| Shares Outstanding (Basic) | 9.9M | 6.3M | 5.1M | 85.4M | 85.4M | 76.2M | 7.9M |
| Shares Outstanding (Diluted) | 9.9M | 6.3M | 5.1M | 85.4M | 85.4M | 76.2M | 7.9M |
| Dividends Per Share | — | — | — | — | — | — | — |